<div>
    <div>
        <!-- Section 1 -->
        <div class="bg-custom-gray-100 py-12" id="overview">
            <div class="container">
                <h1 class="text-center text-[44px] font-bold">Invest in a Better Way to Treat Cancer </h1>
                <div class="grid grid-cols-1 lg:grid-cols-12 gap-6 items-center">
                    <div class="lg:col-span-6 order-2 lg:order-1">
                        <h2 class="text-3xl font-medium mt-6 leading-none">The CancerVax Way</h2>
                        <div class="pt-4">
                            <ul class="[&>li]:text-2xl [&>li]:tracking-[.05px] [&>li]:mb-2 max-w-[600px] list-disc pl-10 my-6">
                                <li>10 million people died last year because the body does not easily recognize and kill cancer cells.</li>
                                <li>However, the body is very good at killing diseases that it recognizes, such as measles.</li>
                                <li>Our unique technology disguises cancer cells to look like measles and "tricks" the body into killing them.</li>
                            </ul>
                        </div>
                        <div class="mt-12">
                            <a href="https://cancervax.directinvest.io/purchase/65664bc380017111b27593bf/" class="block text-lg font-semibold max-w-[318px] mx-auto uppercase cursor-pointer text-center rounded-2xl !p-2 bg-[#ffa41b] !border-[#b76e00] !border-b-[6px]" target="_blank">Invest Here <span class="block text-center text-xs uppercase font-medium">Secure Direct Invest Platform</span></a>
                            <p class="text-2xl bg-custom-teal-100 text-custom-gray-100 px-4 py-3 mt-10 w-fit mx-auto rounded-xl">Previously Raised $4.8 million of Funding</p>
                        </div>
                    </div>
                    <div class="lg:col-span-6 order-1 lg:order-2">
                        <div class="mt-6 mb-12 lg:max-w-[500px]">
                            <h3 class="text-2xl leading-none font-semibold mb-4 text-center text-custom-teal-100">Short Explainer Video</h3>
                            <div class="banner-video-top m-0 position-relative">
                                <a href="https://www.youtube.com/watch?v=PXBNJe3nHp0" class="relative">
                                    <img src="https://i.ytimg.com/vi/PXBNJe3nHp0/maxresdefault.jpg" alt="hero" class="border-custom-teal-100 border-[12px] rounded-xl">
                                    <i class="far fa-play-circle text-6xl text-white shadow-md rounded-[50%] bg-transparent absolute top-1/2 left-1/2 -translate-x-2/4 -translate-y-2/4"></i>
                                </a>
                            </div>

                        </div>
                        <div class="lg:max-w-[500px]">
                            <a href="https://www.youtube.com/watch?v=jfXTYVtlbFE" class="relative">
                                <img src="https://i.ytimg.com/vi/jfXTYVtlbFE/maxresdefault.jpg" alt="hero" class="rounded-xl">
                                <i class="far fa-play-circle text-6xl text-white shadow-md rounded-[50%] bg-transparent absolute top-1/2 left-1/2 -translate-x-2/4 -translate-y-2/4"></i>
                            </a>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- NavBar -->
        <div class="bg-custom-gray-100 pb-6 sm:sticky top-[160px] z-10" id="nav-investor">
            <div class="container">
                <div class="flex justify-center">
                    <ul class="flex flex-wrap justify-around w-full lg:w-fit px-3 lg:px-0 border-custom-gray-300 border-b-2 [&_a]:text-base lg:[&_a]:text-lg [&_a]:!leading-[58px] [&_a]:font-medium [&_li]:pt-3 lg:[&_a]:px-5">
                        <li>
                            <a href="#overview">Overview</a>
                        </li>
                        <li>
                            <a href="#terms">Terms</a>
                        </li>
                        <li>
                            <a href="/news" target="_blank">Updates</a>
                        </li>
                        <li>
                            <a href="#bonus-shares">Bonus Shares</a>
                        </li>
                        <li>
                            <a href="/faqs" target="_blank">FAQ</a>
                        </li>
                    </ul>
                </div>
            </div>
        </div>

        <div>
            <div class="container">
                <div class="grid grid-cols-1 lg:grid-cols-12 gap-6">
                    <div class="lg:col-span-7">

                        <!-- 1st section -->
                        <div class="pt-12 [&_p]:text-xl [&_p]:mb-4 [&_p]:tracking-normal">
                            <p><strong>CancerVax is a pre-clinical biotech company</strong> developing a novel Universal Cancer Treatment Platform that will be customizable, as an injection, to treat many types of cancer. </p>

                            <p> Our innovative approach <strong>DETECTS, MARKS, and KILLS</strong> only cancer cells. By making cancer cells “look” like well immunized common diseases such as measles or chickenpox, we intend to use the body’s natural immune system to easily kill cancer cells. </p>


                            <p> We look forward to the day when treating cancer will be as simple as getting a shot – a better way to treat cancer.</p>
                        </div>

                        <!-- 2nd Section -->
                        <div class="pt-12">
                            <h3 class="text-[32px] font-medium leading-none">Reasons to Invest</h3>

                            <div class="mt-12 [&_p]:text-[15px] [&_p]:leading-5 [&_span]:font-semibold">
                                <div class="flex flex-col lg:flex-row gap-4 mb-10">
                                    <div class="bg-custom-teal-100 text-white text-xl leading-10 max-h-10 max-w-11 min-w-11 text-center font-semibold rounded-md">1</div>
                                    <p>According to the American Cancer Society, <strong>cancer was the second leading cause of death in the United States in 2023<sup>(1)</sup>,</strong> According to Fortune Business Insights, the global cancer drugs market is projected to grow from $205 billion in 2023 to $484 billion by 2030 <sup>(2)</sup>. </p>
                                </div>
                                <div class="flex flex-col lg:flex-row gap-4 mb-10">
                                    <div class="bg-custom-teal-100 text-white text-xl leading-10 max-h-10 max-w-11 min-w-11 text-center font-semibold rounded-md">2</div>
                                    <p> While we don’t have a to prevent cancer, our objective is to develop our Universal Cancer Vaccine platform so that it can be customized to treat a broad spectrum of cancer types and substantially decrease the number of cancer-related fatalities. </p>
                                </div>

                                <div class="flex flex-col lg:flex-row gap-4 mb-10">
                                    <div class="bg-custom-teal-100 text-white text-xl leading-10 max-h-10 max-w-11 min-w-11 text-center font-semibold rounded-md">3</div>
                                    <p>CancerVax is led by an experienced team of biotech experts, cancer researchers and marketing executives who are working with development partners to create its innovative Universal Cancer Treatment Platform.</p>
                                </div>
                                <div class="flex flex-col lg:flex-row gap-4 mb-10">
                                    <div class="bg-custom-teal-100 text-white text-xl leading-10 max-h-10 max-w-11 min-w-11 text-center font-semibold rounded-md">4</div>
                                    <p>CancerVax has previously raised over <span>$4.8 million in funding.</span></p>
                                </div>
                                <div class="flex flex-col lg:flex-row gap-4 mb-10">
                                    <div class="bg-custom-teal-100 text-white text-xl leading-10 max-h-10 max-w-11 min-w-11 text-center font-semibold rounded-md">5</div>
                                    <p>CancerVax is creating a better way to treat cancer.</p>
                                </div>
                            </div>
                        </div>

                        <!-- 3rd Section -->
                        <div class="bg-custom-teal-100 p-10 rounded-md">
                            <div>
                                <h3 class="text-white text-4xl font-medium break-words text-center leading-snug">Massive Market Opportunity</h3>
                            </div>
                            <div>
                                <div class="grid grid-cols-1 lg:grid-cols-3 gap-5 items-center">
                                    <div class="lg:col-span-2 pt-4 lg:pt-12">
                                        <h4 class="text-white text-2xl md:text-3xl font-medium leading-snug mb-4">How big is the biotechnology market?</h4>
                                        <p class="text-white text-lg leading-snug font-normal tracking-[0.78px]">According to Precedence Research, the global biotechnology market is projected to grow from $1.3 trillion in 2023 to <span>$3.2 trillion by 2030<sup>(3)</sup></span></p>
                                    </div>
                                    <div class="lg:col-span-1">
                                        <div class="bg-white text-center px-8 py-4 rounded-md w-full sm:w-fit mx-auto">
                                            <span>Biotech <br>
                                                $3.2 trillion</span>
                                        </div>
                                    </div>
                                </div>
                                <div class="grid grid-cols-1 lg:grid-cols-3 gap-5 items-center">
                                    <div class="lg:col-span-2 pt-4">
                                        <h4 class="text-white text-2xl md:text-3xl font-medium leading-snug mb-4">How big is the cancer drug development market?</h4>
                                        <p class="text-white text-lg leading-snug font-normal tracking-[0.78px]">According to Fortune Business Insights, the global oncology drugs market is projected to grow from $205 billion in 2023 to <span>$484 billion by 2030</span></p>
                                    </div>
                                    <div class="lg:col-span-1">
                                        <div class="bg-white text-center px-8 py-4 rounded-md w-full sm:w-fit mx-auto">
                                            <span>Cancer <br>
                                                $484 billion</span>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <!-- 4th Section -->
                        <div class="pt-16">
                            <h2 class="text-[32px] font-medium leading-none mb-8">Development Partners</h2>
                            <div class="grid grid-cols-1 lg:grid-cols-3 gap-5">
                                <div class="lg:col-span-1">
                                    <div class="dev-partners-img">
                                        <img src="./assets/images/development-partners-1.png" class="w-[300px] lg:w-auto" alt="Development Partners">
                                    </div>
                                </div>
                                <div class="lg:col-span-2">
                                    <p class="text-lg leading-snug tracking-[0.78px] font-normal">With more than <strong>500 physicians and scientists working on the forefront of cancer discoveries</strong>, the UCLA Health Jonsson Comprehensive Cancer Center is a leader in providing both experimental and traditional cancer treatments. Working with a team of world class cancer researchers and practicing oncologists at UCLA, CancerVax began the initial development of its novel Universal Cancer Treatment platform. Also working with CancerVax, UCLA developed a promising cancer drug candidate – a single-disease specific immunotherapy targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults.
                                    </p>
                                </div>
                            </div>
                            <div class="grid grid-cols-1 lg:grid-cols-3 gap-5 mt-12">
                                <div class="lg:col-span-1">
                                    <div class="dev-partners-img">
                                        <img src="./assets/images/flashpoint.png" class="w-[300px] lg:w-auto" alt="Development Partners">
                                    </div>
                                </div>
                                <div class="lg:col-span-2">
                                    <p class="text-lg leading-snug tracking-[0.78px] font-normal">Flashpoint was founded on nanotechnology developed over the past 10 years in the laboratory of Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University and 2024 winner of the prestigious Kavli Prize in Nanoscience. <strong>Flashpoint’s groundbreaking nanotechnology discovery platform</strong> enables the development of therapeutic candidates with superior product profiles. Validated in numerous in-vivo models, this technology has transformed components that are ineffective in conventional formulations into curative cancer immunotherapies. CancerVax is working with Flashpoint to deliver its novel Universal Cancer Treatment therapies using Flashpoint’s nanoparticle technology.
                                    </p>
                                </div>
                            </div>
                        </div>

                        <!-- 5h Section -->
                        <div class="mt-24 mb-10">
                            <h3 class="text-[32px] font-medium leading-none mb-8">Our Scientific Team</h3>
                            <div class="grid grid-cols-1 lg:grid-cols-2 gap-6 mt-6">
                                <div class="lg:col-span-1">
                                    <div class="team-box">
                                        <div class="team-box-img">
                                            <a href="#">
                                                <img src="./assets/images/george.png" class="w-[310px] mx-auto mb-7" alt="john">
                                            </a>
                                        </div>
                                        <h5 class="text-base font-semibold mb-1 cursor-pointer tracking-[1.2px] text-center">
                                            George Katibah, <span>PhD</span>
                                        </h5>
                                        <p class="text-sm font-medium leading-8 text-center">
                                        Chief Scientific Officer
                                        </p>
                                        <div class="hidden">
                                            <ul class="[&>li]:text-2xl [&>li]:tracking-[.05px] list-disc pl-10 my-6">
                                                <li>Expert in the discovery, development, and translation of novel therapies across diverse therapeutic modalities</li>
                                                <li>Deep background in immunology and the tumor microenvironment</li>
                                                <li>Broad therapeutic domain expertise, including oncology, immunology, personalized medicine, and infectious diseases</li>
                                                <li>Part of teams that developed the first-in-human drug candidates, including small molecule STING agonists and personalized cancer neoantigen vaccine</li>
                                                <li>Co-authored more than 16 scientific papers and inventor on 3 issued U.S. patents and multiple pending applications</li>
                                                <li>Formerly Director of Discovery Biology at RAPT Therapeutics</li>
                                                <li>Formerly Senior Scientist and Head of Biochemistry at Aduro Biotech</li>
                                                <li>Received his B.S. in Plant Sciences from the University of California, Santa Cruz</li>
                                                <li>Received his PhD in Molecular and Cell Biology from the University of California, Berkeley</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                                <div class="lg:col-span-1">
                                    <div class="team-box">
                                        <div class="team-box-img">
                                            <a href="#">
                                                <img src="./assets/images/adam-grant.png" class="w-[310px] mx-auto mb-7" alt="john">
                                            </a>
                                        </div>
                                        <h5 class="text-base font-semibold mb-1 cursor-pointer tracking-[1.2px] text-center">
                                            Adam Grant, <span>PhD</span>
                                        </h5>
                                        <p class="text-sm font-medium leading-8 text-center">
                                            Principal Scientist
                                        </p>
                                        <div class="hidden">
                                            <ul class="[&>li]:text-2xl [&>li]:tracking-[.05px] list-disc pl-10 my-6">
                                                <li>An inventor of the Company’s Universal Cancer Treatment platform</li>
                                                <li>Expert computational biologist using next generation sequencing data to identify new drug targets and biomarkers of response to cancer therapeutics </li>
                                                <li>Formerly Bioinformatician at Xenter Medical Technologies</li>
                                                <li>Formerly Computational Scientist at RAPT Therapeutics</li>
                                                <li>Invented software to improve cancer antigen detection</li>
                                                <li>Invented a gene-signature approach to select treatment for breast cancer</li>
                                                <li>Received his B.S in Bioinformatics from Brigham Young University</li>
                                                <li>Received his PhD in Cancer Biology with an emphasis in Bioinformatics from the University of Arizona</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                           
                                <div class="lg:col-span-1">
                                    <div class="team-box">
                                        <div class="team-box-img">
                                            <a href="#">
                                                <img src="./assets/images/lakey.png" class="w-[310px] mx-auto mb-7" alt="john">
                                            </a>
                                        </div>
                                        <h5 class="text-base font-semibold mb-1 cursor-pointer tracking-[1.2px] text-center">
                                            Jonathan Lakey, <span>PhD</span>
                                        </h5>
                                        <p class="text-sm font-medium leading-8 text-center">
                                            Chief Scientific Advisor
                                        </p>
                                        <div class="hidden">
                                            <ul class="[&>li]:text-2xl [&>li]:tracking-[.05px] list-disc pl-10 my-6">
                                                <li>An inventor of the famous “Edmonton Protocol” for treating Type 1 diabetes</li>
                                                <li>Extensive experience in the fields of oncology, stem cells, and organ transplantation</li>
                                                <li>Currently Professor Emeritus at University of California, Irvine.</li>
                                                <li>Formerly Postdoctoral Fellow, Cryobiology Research Institute Indiana University Indianapolis
                                                </li>
                                                <li> Formerly Postdoctoral Fellow, Clinical tissue banking University of Washington</li>
                                                <li>Formerly Postdoctoral Fellow, Tissue banking/cryopreservation University of Alberta</li>
                                                <li>Published over 495 scientific papers, 45 books, and over 500 scientific abstracts</li>
                                                <li>Advisor to many biotech companies</li>
                                                <li>Received his BS in Zoology/Animal Biology from University of Alberta</li>
                                                <li>Received his MS in Zoology/Animal Biology from University of Alberta</li>
                                                <li>Received his PhD of Islet transplantation, diabetes, and medical devices from University of Alberta</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                                <div class="lg:col-span-1">
                                    <div class="team-box">
                                        <div class="team-box-img">
                                            <a href="#">
                                                <img src="./assets/images/amit-indap.png" class="w-[310px] mx-auto mb-7" alt="john">
                                            </a>
                                        </div>
                                        <h5 class="text-base font-semibold mb-1 cursor-pointer tracking-[1.2px] text-center">
                                            Amit Indap, <span>PhD</span>
                                        </h5>
                                        <p class="text-sm font-medium leading-8 text-center">
                                            Scientific Advisor
                                        </p>
                                        <div class="hidden">
                                            <ul class="[&>li]:text-2xl [&>li]:tracking-[.05px] list-disc pl-10 my-6">
                                                <li>Expert in immuno-oncology involving mRNA vaccine development for cancer and COVID, CDx development using comprehensive genomic profiling of tumors, ctDNA analysis of clinical samples, NGS based antibody discovery, and single cell RNAseq analysis</li>
                                                <li>Formerly Principal Scientist at Pfizer</li>
                                                <li>Formerly Scientist at Good Start Genetics</li>
                                                <li>Formerly Research Scientist at Human Longevity, Inc.</li>
                                                <li>Formerly Bioinformatics Scientist at Illumina</li>
                                                <li>Formerly Senior Manager of Bioinformatics at Xencor</li>
                                                <li>Received his B.S. in Molecular and Cellular Biology and minor in Computer Science From University of Arizona</li>
                                                <li>Received his M.S. degree in bioinformatics from Medical College of Wisconsin</li>
                                                <li>Received his PhD in Biology from Boston College</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                                <div class="lg:col-span-1">
                                    <div class="team-box">
                                        <div class="team-box-img">
                                            <a href="#">
                                                <img src="./assets/images/matthew-spear.png" class="w-[310px] mx-auto mb-7" alt="john">
                                            </a>
                                        </div>
                                        <h5 class="text-base font-semibold mb-1 cursor-pointer tracking-[1.2px] text-center">
                                            Matthew Spear, <span>MD</span>
                                        </h5>
                                        <p class="text-sm font-medium leading-8 text-center">
                                            Scientific Advisor
                                        </p>
                                        <div class="hidden">
                                            <ul class="[&>li]:text-2xl [&>li]:tracking-[.05px] list-disc pl-10 my-6">
                                                <li>Expert in guiding the development and commercialization of new drugs, therapies, and biotech products as Chief Development Officer and Chief Medical Officer of biotech companies</li>
                                                <li>Dr. Spear has been working in oncology and gene therapy research and development for over 30 years</li>
                                                <li>Currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma</li>
                                                <li>Formerly Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer.</li>
                                                <li>Formerly led multiple oncology clinical development programs at Pfizer</li>
                                                <li>Formerly served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals</li>
                                                <li>Formerly Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals</li>
                                                <li>Formerly Vice-President at Incyte and Sangamo Therapeutics</li>
                                                <li>Formerly Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products</li>
                                                <li>Received a B.A. degree from the Johns Hopkins University</li>
                                                <li>Received his M.D. degree from Stanford University</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                                <div class="lg:col-span-1">
                                    <div class="team-box">
                                        <div class="team-box-img">
                                            <a href="#">
                                                <img src="./assets/images/steven-warner.png" class="w-[300px] mx-auto mb-7" alt="john">
                                            </a>
                                        </div>
                                        <h5 class="text-base font-semibold mb-1 cursor-pointer tracking-[1.2px] text-center">
                                            Steven Warner, <span>PhD</span>
                                        </h5>
                                        <p class="text-sm font-medium leading-8 text-center">
                                            Scientific Advisor
                                        </p>
                                        <div class="hidden">
                                            <ul class="[&>li]:text-2xl [&>li]:tracking-[.05px] list-disc pl-10 my-6">
                                                <li>Specializes in small molecule drug discovery, new screening platforms in drug discovery, and translational research focusing on cancer therapeutics</li>
                                                <li>He is an expert in the discovery of novel cancer agents and has played integral roles in moving multiple compounds into clinical trials.</li>
                                                <li>Currently Senior VP and Head of US Research at Sumitomo Pharma America</li>
                                                <li>Formerly Manager of Discovery Biology at SuperGen</li>
                                                <li>Formerly Senior Manager of Drug Discovery at Huntsman Cancer Institute</li>
                                                <li>Formerly VP of Drug Discovery at Tolero Pharmaceuticals</li>
                                                <li>Received his B.S. in Biology from Brigham Young University</li>
                                                <li>Received his PhD in Pharmaceutical Sciences from the University of Arizona</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <!-- 6th Section -->
                        <div class="py-12">
                            <h3 class="text-[23px] sm:text-[32px] font-medium leading-none mb-8">The Old Way of Treating Cancer</h3>
                            <div class="[&_p]:text-[17px] [&_p]:leading-snug [&_p]:tracking-normal [&_p]:mt-4 [&_p]:font-normal">
                                <p>For decades, surgery, chemotherapy and radiation therapy have been the standards of care for cancer treatment, and often the only options. They operate on the basic premise that cancer cells are fast growing cells, so using powerful toxic chemicals (chemotherapy) or powerful x-rays (radiation) they hope to kill those cells to stop the cancer.
                                </p>
                                <p>The problem is that these treatments are not always very targeted, so they also kill normal fast-growing cells, such as hair cells, intestine cells, mouth-lining cells and others. This inadvertent side effect of killing healthy cells is what causes the debilitating side effects of chemotherapy and radiation, and a reduced quality of life for cancer patients.</p>
                                <p>Using “chemo” has been likened to throwing a grenade into the body with the hope that it will kill the cancer and not the body.
                                </p>
                                <div class="mt-14 max-w-[530px] mx-auto">
                                    <img src="./assets/images/solution2.png" alt="hero">
                                </div>
                            </div>
                        </div>

                        <!-- 7th Section -->
                        <div class="py-12">
                            <h3 class="text-[23px] sm:text-[32px] font-medium leading-none mb-8">A Better Way to Treat Cancer
                                - Our Universal Cancer Treatment Platform</h3>
                            <h4 class="text-[26px] font-medium mt-6 mb-3">The Problem​</h4>
                            <ul class="[&>li]:text-[17px] [&>li]:tracking-normal [&>li]:leading-6 list-disc pl-5 my-6">
                                <li>The body’s immune system is very good at killing foreign pathogens, such as the measles virus. But it’s not very good at killing cancer cells because cancer cells were originally normal cells and not foreign pathogens. This is why cancer grows undetected and is so hard to treat.</li>
                            </ul>

                            <h4 class="text-[23px] sm:text-[26px] font-medium mt-6 mb-3">The Solution​</h4>
                            <ul class="[&>li]:text-[17px] [&>li]:tracking-normal [&>li]:leading-6 list-disc pl-5 my-6">
                                <li>We are developing a novel technology that will precisely detect cancer cells
                                    and force them to produce special proteins to “look” like common diseases
                                    for which a strong immunity already exists – such as measles or chickenpox.
                                    Then, the immune system will automatically destroy these disguised cancer
                                    cells as if they were known foreign pathogens. </li>
                                <li class="mt-4">Our technology is packaged into a nanoparticle that is programmable to seek out only cancer cells and uses a novel 2-step strategy to precisely detect cancer cells.</li>

                                <ul class="[&>li]:text-[17px] [&>li]:tracking-normal [&>li]:leading-6 list-disc pl-5 my-6">
                                    <li>Step 1 - Detect cell surface markers <strong>outside the cell</strong></li>
                                    <li>Step 2 - Detect cancer genetic signatures <strong>inside the cell</strong>​</li>
                                </ul>
                            </ul>

                        </div>

                        <!-- 8th Section -->
                        <div class="py-12">
                            <h3 class="text-[23px] sm:text-[32px] font-medium leading-none mb-8">Features of Our Universal Cancer Treatment Platform</h3>
                            <ul class="[&>li]:text-[17px] [&>li]:tracking-normal [&>li]:leading-6 [&>li]:mb-4 list-disc pl-5 my-6">
                                <li>A Customizable Platform for treating many types of cancer</li>
                                <li>Makes cancer cells look like well immunized diseases (chickenpox, measles, etc.)</li>
                                <li>Novel 2-step precise detection of cancer cells (outside cell signature + inside cell signature)​</li>
                                <li>DETECT, MARK, and KILL only cancer cells​</li>
                                <li>Proprietary artificial intelligence and machine learning algorithms to find cellular signatures for various cancer types​</li>
                                <li>Built on tried-and-true messenger RNA (mRNA) technology​</li>
                                <li>Built on tried-and-true lipid nanoparticle technology​</li>
                                <li>2 patent applications</li>
                            </ul>
                            <div class="pt-12 [&>p]:text-[17px] [&>p]:tracking-normal [&>p]:leading-6 [&>p]:mt-6">
                                <h3 class="text-[23px] sm:text-[32px] font-medium leading-none mb-8"> Our Future</h3>
                                <p>The CancerVax business model involves partnering with experienced cancer research institutions and technology providers to develop new life-changing drugs, followed by plans to license and/or sell our drugs and/or our technologies to major pharmaceutical companies.</p>

                                <p>As a biotech company, our goal is to create value for our company and our shareholders at every step of incremental success we make on the path to FDA approval.</p>

                                <p>From discovery, to optimization, to pre-clinical trials, and additional future phases (phase 1 clinical trials, phase 2 clinical trials, phase 3 clinical trials), every step is a value inflection point that CancerVax believes could increase the company’s value and bring it one step closer to curing cancer.</p>

                                <p>Join CancerVax and invest in our breakthrough technology to help treat cancer!</p>
                            </div>
                        </div>



                        <!-- 5th Section -->
                        <div class="py-12 [&_p]:text-[17px] [&_p]:leading-snug [&_p]:tracking-normal [&_p]:mt-4 [&_p]:font-normal">

                            <h3 class="text-[23px] sm:text-[32px] font-medium leading-none mb-8"> Join Us to Help Beat Cancer</h3>

                            <p>Cancer immunotherapy is the next generation weapon in the fight against cancer. It uses the body’s own immune system to target and kill cancer cells. </p>
                            <p>Pharmaceutical research is booming from the effects of the COVID-19 pandemic, where the medical community learned how to use mRNA to recognize and fight specific disease states.</p>
                            <p>CancerVax is using a "Smart mRNA" concept to create a novel cancer immunotherapy treatment that uses a patient's immune system to detect, mark, and kill cancer -- a better way to treat cancer.</p>

                            <a href="https://cancervax.directinvest.io/purchase/65664bc380017111b27593bf/" target="_blank" rel="noopener noreferrer">
                                <img src="./assets/images/invest-microscope.png" alt="hero" class="mt-14">
                            </a>

                        </div>

                        <!-- 6th Section -->
                        <div class="py-12" id='terms'>
                            <h3 class="text-[23px] sm:text-[32px] font-medium leading-none mb-8">Terms</h3>
                            <div class="rounded-[10px] shadow-[0_0px_10px_5px_rgba(0,0,0,0.1)] mt-8 mb-24 p-8">
                                <div class="grid grid-cols-1 md:grid-cols-2 gap-x-6">
                                    <div>
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">OFFERING SIZE</div>
                                        <div class="text-base sm:text-xl font-semibold leading-tight mb-7 md:mb-10">$5,000,000</div>
                                    </div>
                                    <div>
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">PRICE FOR SHARE</div>
                                        <div class="text-base sm:text-xl font-semibold leading-tight mb-7 md:mb-10">$2.10</div>
                                    </div>
                                    <div>
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">MIN INVESTMENT</div>
                                        <div class="text-base sm:text-xl font-semibold leading-tight mb-7 md:mb-10">$525</div>
                                    </div>
                                    <div>
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">OFFERING TYPE</div>
                                        <div class="text-base sm:text-xl font-semibold leading-tight mb-7 md:mb-10">Equity</div>
                                    </div>
                                    <div>
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">ASSET TYPE</div>
                                        <div class="text-base sm:text-xl font-semibold leading-tight mb-7 md:mb-10">Common Stock</div>
                                    </div>
                                    <div>
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">SHARES OFFERED</div>
                                        <div class="text-base sm:text-xl font-semibold leading-tight mb-7 md:mb-10">Common Stock</div>
                                    </div>
                                    <div class="term-blo d-flex flex-column">
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">OFFERING CIRCULAR</div>
                                        <a href="/filings" class="text-base sm:text-xl font-semibold leading-tight md:mb-10 last-offer mb-0 underline">Click Here</a>
                                    </div>
                                    <div>
                                        <div class="text-base sm:text-lg font-normal leading-tight mb-1">BROKER DEALER</div>
                                        <a href="https://dalmoregroup.com/about-dalmore/" target="_blank" rel="noopener noreferrer">
                                            <img src="./assets/images/DallMore.png" class="w-[200px]" alt="dallmore">
                                        </a>
                                    </div>
                                </div>
                            </div>
                            <a name="bonus-shares" style="position: relative; top:-260px"></a>
                            <h4 class="text-[23px] sm:text-[28px] font-medium mt-6 mb-3">Bonus Shares</h4>
                            <h5 class="text-[42px] font-medium mt-6 mb-3">Invest More And Get More!</h5>
                            <p class="text-[17px] leading-snug tracking-normal mt-4 font-normal">Investors in this offering are eligible to receive bonus shares of Common Stock, which effectively gives them a discount on their investment.  Investors receiving the Bonus Shares will pay an effective price less than the $2.10 offering price.</p>
                            <div class="rounded-[10px] shadow-xl overflow-hidden mt-8 sm:mt-12 mb-11 sm:mb-20">
                                <table class="w-full table-fixed lg:table-auto border-collapse">
                                    <thead class="[&_th]:text-base [&_th]:md:text-xl [&_th]:text-center [&_th]:font-semibold [&_th]:bg-black [&_th]:text-custom-white-100 [&_th]:px-4 [&_th]:py-4 [&_th]:md:px-4 [&_th]:md:py-6">
                                        <tr>
                                            <th>Total Investment</th>
                                            <th>Bonus Shares</th>
                                            <th>Effective Price Per Share</th>
                                        </tr>
                                    </thead>
                                    <tbody class="[&_td]:text-base [&_td]:text-center [&_td]:font-medium [&_td]:px-4 [&_td]:py-4 [&_td]:md:px-4 [&_td]:md:py-6 [&_td]:border-b [&_td]:border-gray-100">
                                        <tr>
                                            <td>$1,000</td>
                                            <td>5% Bonus Shares</td>
                                            <td>$2.00</td>
                                        </tr>
                                        <tr>
                                            <td>$1,500</td>
                                            <td>7.5% Bonus Shares</td>
                                            <td>$1.95</td>
                                        </tr>
                                        <tr>
                                            <td>$2,500</td>
                                            <td>10% Bonus Shares</td>
                                            <td>$1.91</td>
                                        </tr>
                                        <tr>
                                            <td>$5,000</td>
                                            <td>15% Bonus Shares</td>
                                            <td>$1.83</td>
                                        </tr>
                                        <tr>
                                            <td>$10,000</td>
                                            <td>20% Bonus Shares</td>
                                            <td>$1.75</td>
                                        </tr>
                                        <tr>
                                            <td>$25,000</td>
                                            <td>25% Bonus Shares</td>
                                            <td>$1.68</td>
                                        </tr>
                                        <tr>
                                            <td>$35,000</td>
                                            <td>30% Bonus Shares</td>
                                            <td>$1.62</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>

                            <h4 class="text-[23px] sm:text-[28px] font-medium mt-5 mb-2">Market Statistics</h4>

                            <div class="mb-2">
                                <a href="https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html" class="text-sm underline" target="_blank">
                                    1. (2023) American Cancer Society
                                </a>
                            </div>

                            <div class="mb-2">
                                <a href="https://www.globenewswire.com/news-release/2023/08/16/2726224/0/en/Oncology-Drugs-Market-Size-to-Surpass-USD-484-32-Billion-by-2030-exhibiting-a-CAGR-of-13-0.html" class="text-sm underline" target="_blank">
                                    2. (2023) Fortune Business Insights
                                </a>
                            </div>


                            <div class="mb-2">
                                <a href="https://www.precedenceresearch.com/biotechnology-market" class="text-sm underline" target="_blank">
                                    3. (2023) Precedence Research
                                </a>
                            </div>
                            <h4 class="text-[23px] sm:text-[28px] font-medium mt-12 mb-2">Disclaimer</h4>
                            <p class="text-[17px] leading-snug tracking-normal font-normal"> THESE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARDLOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.</p>

                            <p class="text-[17px] leading-snug tracking-normal mt-8 font-normal"> PLEASE NOTE INVESTORS IN THIS OFFERING WILL BE CLIENTS OF THE ISSUER AND NOT DALMORE GROUP, LLC (“DALMORE”), A REGISTERED BROKER-DEALER AND MEMBER FINRA/SIPC. DALMORE’S ROLE IN THE TRANSACTION IS TO FACILITATE BACK OFFICE AND REGULATORY FUNCTIONS RELATED TO THE REGULATION A TRANSACTION, AND ACTS ONLY AS THE BROKER/DEALER OF RECORD FOR THE OFFERING LISTED. DALMORE IS NOT PROVIDING INVESTMENT ADVICE OR RECOMMENDATIONS, OR LEGAL OR TAX ADVICE.</p>

                            <p class="text-[17px] leading-snug tracking-normal mt-8 font-normal">THIS REG A INVESTMENT IS SPECULATIVE, ILLIQUID, AND INVOLVES A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT. ALL INVESTORS SHOULD MAKE THEIR OWN DETERMINATION, WITH THE ASSISTANCE OF THEIR OWN FINANCIAL OR OTHER ADVISORS, AS TO WHETHER OR NOT TO MAKE ANY INVESTMENT, BASED ON THEIR OWN INDEPENDENT EVALUATION, ANALYSIS AND CIRCUMSTANCES.</p>

                            <p class="text-[17px] leading-snug tracking-normal mt-8 font-normal"> AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AT: <a href="/filings">Click Here</a></p>
                        </div>

                    </div>
                    <div class="hidden lg:block lg:col-span-5 ralative">
                        <div class="bg-custom-gray-100 shadow-[0_0px_10px_5px_rgba(0,0,0,0.1)] sticky top-[300px] my-12 mx-auto max-w-[370px] rounded-[20px] p-5">
                            <div class="flex justify-center">
                                <a href="#" class="inline-block text-lg font-semibold w-full uppercase cursor-pointer text-center rounded-2xl !p-2 bg-[#ffa41b] !border-[#b76e00] !border-b-[6px]">Invest Now<span class="block text-center text-xs uppercase font-medium">Secure Direct Invest Platform</span></a>
                            </div>
                            <div class="flex justify-between mt-10">
                                <div>
                                    <p class="text-base font-normal">PRICE</p>
                                    <p class="text-lg font-semibold mt-2 mb-5">$2.10</p>
                                    <p class="text-base font-normal">BONUS SHARES</p>
                                    <p class="text-lg font-semibold underline mt-2 mb-5">Up to 30%</p>
                                </div>
                                <div>
                                    <p class="text-base font-normal">MINIMUM</p>
                                    <p class="text-lg font-semibold mt-2 mb-5">$525.00 </p>
                                    <p class="text-base font-normal">OFFERING CIRCULAR </p>
                                    <p class="text-lg font-semibold underline mt-2 mb-5">Click Here</p>
                                </div>
                            </div>
                            <div class="max-w-[215px] mx-auto mt-2">
                                <p class="font-semibold text-lg text-center">BROKER DEALER</p>
                                <img src="assets/images/DallMore.png" alt="hero">
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="flex lg:hidden justify-around items-center fixed z-10 left-0 right-0 bottom-0 bg-white p-2">
                <div class="">
                    <a href="#bonus-shares" class="text-lg font-bold underline">Earn Bonus Shares</a>
                    <div>
                        <a href="/filings" class="text-lg font-bold underline">SEC Filings</a>
                    </div>
                </div>
                <div class="flex justify-center w-[378px]">
                    <a href="https://cancervax.directinvest.io/purchase/65664bc380017111b27593bf/"  class="inline-block text-base font-semibold w-full uppercase cursor-pointer text-center rounded-2xl !p-2 bg-[#ffa41b] !border-[#b76e00] !border-b-[6px]" target="_blank">Invest Here <span class="block text-[12px] font-medium">Secure Direct Invest Platform</span></a>
                </div>
            </div>
        </div>

        <!-- 7th Section -->
        <div class="bg-custom-gray-100">
            <div class="container">
                <div class="py-10 md:py-20 grid grid-cols-1 md:grid-cols-12 md:gap-6">
                    <div class="md:col-span-7">
                        <div class="text-base md:text-3xl font-bold text-center md:text-left mb-5">Keep up with our progress by subscribing to
                            our email newsletter!
                        </div>
                    </div>
                    <div class="md:col-span-5 relative">
                        <form action="https://submit.jotform.com/submit/242775392698071/" method="POST" class="email-input">
                            <input type="hidden" name="formID" value="242775392698071" />
                            <input type="email" id="input_3" name="q3_email" class="w-full border border-custom-teal-100 text-base font-normal p-[10px] rounded-md min-h-[50px] pr-[120px] hidden md:block" placeholder="Enter your email">
                            <div class="mt-16 md:mt-2" data-type="control_captcha" id="id_4">
                                <label class="text-[15px] font-normal leading-6" id="label_4" for="input_4" aria-hidden="false"> Please verify that you are human<span>*</span> </label>
                                <div id="cid_4" class="form-input-wide jf-required" data-layout="full">
                                    <section data-wrapper-react="true">
                                        <div id="hcaptcha_input_4" class="h-captcha" data-siteKey="772f4a50-7161-425e-8cd5-4d7e361ab765" data-callback="hcaptchaCallbackinput_4" data-expired-callback="hcaptchaExpiredCallbackinput_4"></div><input type="hidden" id="input_4" class="hidden validate[required]" name="hcaptcha_visible" required="" />
                                        <script type="text/javascript" src="https://hcaptcha.com/1/api.js"></script>
                                    </section>
                                </div>
                            </div>
                            <button type="submit" id="submitNewsletterButton" class="bg-custom-teal-100 text-custom-white-100 cursor-pointer p-[10px] text-xl font-medium border-none rounded-md min-h-[50px] w-full md:w-fit absolute top-0 right-0">Subscribe</button>
                        </form>
                        <script>
                            const submitNewsletterButton = document.getElementById('submitNewsletterButton');

                            function onCaptchaSuccess(token) {
                                document.getElementById('input_4').value = token;
                                submitNewsletterButton.disabled = false;
                            }

                            function onCaptchaExpired() {
                                document.getElementById('input_4').value = '';
                                submitNewsletterButton.disabled = true;
                            }
                        </script>
                        <div class="text-xs font-medium my-2">We care about your data in our privacy policy</div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</div>